Mammographic density by Boyd, Norman F et al.
Available online http://breast-cancer-research.com/supplements/11/S3/S4
Page 1 of 5
(page number not for citation purposes)
Introduction
The present short review will address three questions: What
is the evidence that breast density is a major risk factor for
breast cancer? How is breast density best assessed and
what factors influence breast density? How do you utilize
breast density in the preventative setting?
What is the evidence that breast density is a
major risk factor for breast cancer?
McCormack and dos Santos Silva have reviewed the data on
the association of percentage mammographic density (PMD)
with risk of breast cancer in a systematic meta-analysis of
data for >14,000 cases and 226,000 noncases from 42
studies [1]. They found that PMD was consistently asso-
ciated with risk of breast cancer. Associations were stronger
in studies in the general population, rather than in sympto-
matic women, for percentage density rather than for Wolfe
categories, and in studies of incident cancer rather than
prevalent cancer. The breast cancer risk associated with
density did not differ by age, menopausal status or ethnicity
and cannot be explained by the masking of cancers by dense
tissue [2].
A total of 10 cohort studies have been reported to date, all
carried out as case–control studies nested within cohorts
that used quantitative methods to classify PMD [2-10]. The
interval between the mammogram used to classify PMD and
the date of diagnosis of breast cancer varied from 1 year to
10 years. Methods of classifying PMD in analysis varied
among these studies, but all showed a substantial increase in
breast cancer risk across over the partitions of PMD
examined, with most odds ratios being between 4 and 5.
PMD is associated with a risk of breast cancer at screening
and between screening examinations [2,11].
Mammographic density expressed as either a percentage of
the area of the breast (PMD) or as the area of dense tissue
(cm2) in a mammogram are both positively associated with
risk of breast cancer, but PMD is the stronger association [5].
Conclusions
PMD has a consistent strong influence on breast cancer risk,
is independent of other risk factors, has a larger gradient in
risk than most other risk factors, has an increased risk that
extends for at least 10 years after the mammogram used to
classify density, and carries a risk not explained by masking.
How is breast density best assessed and
what factors influence breast density?
Measurement
Examples of mammographic density of varying extents are
shown in Figure 1. Four principal methods have been used to
date to assess mammographic density. First, Wolfe des-
cribed four categories of density: N1, predominately fat; P1
and P2, ductal prominence in, respectively, <25% or >25%
of the breast; and DY, extensive dysplasia [12,13]. The
Breast Imaging Reporting and Data System (BI-RADS) also
has four categories: 1, predominately fat; 2, scattered densi-
ties; 3, heterogeneously dense; and 4, extremely dense [14].
The third method involves visual estimation of the proportion
of the breast occupied by radiologically dense breast tissue
[15]. Finally, there are computer-assisted methods of measure-
ment (Cumulus and other similar programs) based on
interactive thresholding [16]. Cumulus is illustrated in
Figure 2. An observer places thresholds at the edge of the
breast (red line) and at the edge of the density (green line),
and the areas so defined are recoded by the computer. PMD
is calculated by dividing the dense area by the total area
times 100 and can be treated in analysis as either a
continuous variable or a categorical variable.
These methods differ in their ease of application and in their
reliability. The Wolfe categories have largely been replaced in
the literature by quantitative methods of classification or by
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the BI-RADS score, which is completed in a large proportion
of routine mammograms in the USA. Quantitative assessment
of mammograms using Cumulus or other similar methods of
measurement has been used mostly in research studies as it
requires a trained observer and digitized film images, or
processed images from digital mammography. Reliability
between readers in the use of these methods is modest for
BI-RADS (κ ~ 0.6) [17], intermediate for quantitative
estimation by a radiologist (intraclass correlation coefficient
~ 0.7) [15] and good for Cumulus (intraclass correlation
coefficient ~ 0.9 or greater) [2].
All current methods of assessment use only the two
dimensions of the mammogram, and none take into account
variations in image production or processing. Despite this,
the methods have all been shown to have an association with
risk of breast cancer. Quantitative methods are more time
consuming than are qualitative methods, and require a trained
observer and digitized images, but are more reliable and can
provide information about the separate components of the
ratio of percentage density.
Conclusions
All current methods of assessing density have advantages
and disadvantages, and no method is ideal. All methods have
measurement error. The breast cancer risk associated with
density may be substantially underestimated. Densities on
digital and film mammograms are not identical.
Influences
Age, mammographic density and incidence of breast cancer
The distribution of PMD changes with increasing age
[5,18,19], reflecting the reduction in glandular tissue and
accompanying increase in fat that occurs with increasing age
Figure 1
Examples of mammographic density. (a) 0%. (b) <10%. (c) <25%. (d) <50%. (e) <75%. (f) >75%.
Figure 2
Computer-assisted measurement of mammographic density.[20]. The decline in density with age may seem paradoxical,
as breast cancer incidence increases with age, but this
apparent paradox may be resolved by reference to a model of
breast cancer incidence proposed by Pike and colleagues
[21]. The model is based on the concept that breast tissue
age, or breast tissue exposure rather than chronological age,
is the relevant measure for describing the incidence of breast
cancer. Breast tissue age is closely associated with exposure
of breast tissue to hormones and growth factors, and to the
effects that menarche, pregnancy and menopause have on
these exposures and on susceptibility to carcinogens. As
shown in Figure 3, breast tissue exposure is greatest at the
time of menarche, falls with pregnancy, is further reduced in
the perimenopausal period, and is least after the menopause.
Pike and colleagues showed that cumulative breast tissue
exposure, given by the area under the curve in Figure 3a,
describes the age–incidence curve for breast cancer shown
in Figure 3b.
Breast cancer risk factors
As further described below, average PMD is reduced with
increasing age [19]. PMD is also less extensive in women
who are parous, less extensive in those with a larger number
of live births [22,23], and is reduced by menopause
[18,24,25]. After adjustment for age and other potential
influences, a family history of breast cancer is associated with
more extensive PMD [26]. PMD has consistently been found
to be inversely associated with body weight [27,28], and
greater birth weight and adult height are positively associated
both with PMD [27,29] and with an increased risk of breast
cancer [30-33].
Factors that change mammographic density
Combined hormone therapy, but not estrogen alone, is
associated with an increase in risk of breast cancer [34] and
an increase in PMD [35,35-37]. PMD in postmenopausal
women is reduced by tamoxifen [38] and raloxifene [39],
drugs that reduce breast cancer incidence, and PMD in
premenopausal women is reduced by a gonadotrophin-
releasing hormone agonist [40]. Cuzick and colleagues, in a
study published to date only in abstract form, have reported
an association between a reduction in PMD following use of
tamoxifen and reduction in breast cancer incidence [41]. The
clinical or biological significance of any given change in PMD
is currently unknown.
Heritability
The breast cancer risk factors whose influence was des-
cribed above account for only 20 to 30% of the variation in
PMD observed in the population [24], and genetic factors
might explain some of the unexplained variation of PMD. In
collaboration with John Hopper (Melbourne, Australia) we
carried out two twin studies of substantial size to estimate the
proportion of the variance in PMD that could be explained by
genetic factors [42]. Mammograms were obtained in 951
twin pairs aged 40 to 70 years, in Australia and North
America, and information was collected on the factors
associated with variations in PMD. Details of the findings are
given in [42]. The proportion of the residual variation in PMD
accounted for by additive genetic factors (heritability) was
estimated to be 60% (95% confidence interval = 54 to 66%)
from Australian twins, 67% (95% confidence interval = 59 to
75%) from North American twins, and 63% (95% confidence
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Figure 3
(a) Pike model of mammary carcinogenesis. (b) Age-specific incidence of breast cancer – observed and predicted by the Pike model. Reprinted by
permission from Macmillan Publishers Ltd: Pike and colleagues, Nature © 1983 [21].interval = 59 to 67%) in the combined studies [42]. These
data thus provide an almost exact replication of evidence that
is consistent with a strong genetic influence on PMD. A
subsequent study with 553 twin pairs found similar results
[43]. PMD thus has the characteristics of a quantitative trait.
Conclusions
The association of density with age resembles Pike and
colleagues’ log-incidence breast tissue exposure model.
Mammographic density is influenced by several factors,
including drugs that influence the risk of breast cancer. The
genetic influence is stronger than that of other risk factors.
How do you use breast density in the
preventive setting?
The ability to predict the future occurrence of disease in
individuals allows the improved design and application of
preventive strategies, improved planning of intervention trials,
revision of the risks and benefits associated with preventive
interventions, and improved clinical decision-making [44].
Cardiovascular medicine provides a paradigm for an approach
to disease prevention based on risk prediction, and modifica-
tion of risk factors has been estimated to account for
approximately one-half of the 40% reduction in age-specific
mortality from cardiovascular disease observed over the past
three decades, the remainder of the reduction being attribu-
ted to improvements in treatment [45].
Prediction of the risk of developing breast cancer is less well
developed than for cardiovascular disease [44]. The most
widely used current method of predicting risk of breast
cancer is the Gail model [46], which includes age, age at
menarche, age at first live birth, number of previous benign
breast biopsies, and number of first-degree relatives with
breast cancer.
The addition of PMD (described by the BI-RADS method) to
the Gail model increased the concordance statistic from
0.607 to 0.642, more than did the addition of the seven
SNPs found reproducibly to be associated with breast
cancer (concordance statistic = 0.632). These levels of
individual prediction are no better than modest.
Conclusions
Individual risk prediction using PMD is modest, with or
without other risk factors. Group risk prediction may be useful
in trial design. Mammographic density has not yet been
shown to meet criteria for surrogacy in any setting.
Future research
Research in progress in several centers can be expected in
the next few years to identify the genetic variants associated
with differences in PMD [47]. Events in early life are believed
to have an important influence on later risk of breast cancer
[48], and research into the factors that influence breast
development and breast tissue composition in early life may
provide insight into more effective methods of breast cancer
prevention [49]. Despite the recognized importance of PMD
as a risk factor for breast cancer, we still lack reliable,
automated, quantitative and volumetric methods of measuring
this risk factor – the development of such methods should be
a high priority.
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